StockNews.AI
ABT
Benzinga
209 days

Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall

1. Abbott's Q4 sales rose 7.2% but missed expectations. 2. Medical Device sales grew 13.7%, led by FreeStyle Libre. 3. Diabetes Care sales increased 22.7%, driven by glucose monitors. 4. Abbott expects 2025 EPS of $5.05-$5.25, slightly below consensus. 5. COVID-19 testing sales dropped significantly compared to last year.

4m saved
Insight
Article

FAQ

Why Neutral?

Sales growth was strong but missed consensus expectations. This mixed result can temper investor enthusiasm.

How important is it?

The article provides critical earnings information for ABT, impacting investor perception.

Why Short Term?

Immediate effects from earnings may be priced in quickly. Guidance is cautiously optimistic for 2025.

Related Companies

Related News